CN108117614B - 低分子量肝素 - Google Patents
低分子量肝素 Download PDFInfo
- Publication number
- CN108117614B CN108117614B CN201710374082.XA CN201710374082A CN108117614B CN 108117614 B CN108117614 B CN 108117614B CN 201710374082 A CN201710374082 A CN 201710374082A CN 108117614 B CN108117614 B CN 108117614B
- Authority
- CN
- China
- Prior art keywords
- molecular weight
- heparin
- low molecular
- average molecular
- heparinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940127215 low-molecular weight heparin Drugs 0.000 title claims abstract description 136
- 239000003055 low molecular weight heparin Substances 0.000 claims abstract description 131
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 26
- 230000002265 prevention Effects 0.000 claims abstract description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 132
- 229920000669 heparin Polymers 0.000 claims description 117
- 229960002897 heparin Drugs 0.000 claims description 114
- 108010022901 Heparin Lyase Proteins 0.000 claims description 58
- 238000009826 distribution Methods 0.000 claims description 28
- 108010083213 heparitinsulfate lyase Proteins 0.000 claims description 27
- 108010006406 heparinase II Proteins 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 20
- 102000008186 Collagen Human genes 0.000 claims description 15
- 108010035532 Collagen Proteins 0.000 claims description 15
- 229920001436 collagen Polymers 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 230000000593 degrading effect Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000002440 hepatic effect Effects 0.000 claims description 6
- 230000000116 mitigating effect Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 70
- 239000000047 product Substances 0.000 description 55
- 238000000034 method Methods 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- 206010019668 Hepatic fibrosis Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 229960000610 enoxaparin Drugs 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 206010016654 Fibrosis Diseases 0.000 description 12
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 12
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 12
- 229960002591 hydroxyproline Drugs 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000003176 fibrotic effect Effects 0.000 description 11
- 210000005228 liver tissue Anatomy 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 8
- 238000009835 boiling Methods 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 230000000415 inactivating effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000012466 permeate Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000004570 mortar (masonry) Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000004847 absorption spectroscopy Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000014508 negative regulation of coagulation Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 230000007866 hepatic necrosis Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 241001250090 Capra ibex Species 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 241001643725 Hydrangea febrifuga Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- -1 hepatic Diseases 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611078516 | 2016-11-29 | ||
CN2016110785163 | 2016-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108117614A CN108117614A (zh) | 2018-06-05 |
CN108117614B true CN108117614B (zh) | 2020-09-04 |
Family
ID=62228134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710374082.XA Active CN108117614B (zh) | 2016-11-29 | 2017-05-24 | 低分子量肝素 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108117614B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0244236A2 (en) * | 1986-04-30 | 1987-11-04 | Novo Nordisk A/S | Process for the preparation of LMW Heparin |
EP1033375A1 (en) * | 1997-11-20 | 2000-09-06 | Ikuo Yamashina | Low-molecular heparin modification and remedy for skin ulcer |
CN1286266A (zh) * | 2000-09-22 | 2001-03-07 | 复旦大学 | 低抗凝肝素及其衍生物在制备防治肝纤维化药物中的应用 |
CN1712418A (zh) * | 2005-08-04 | 2005-12-28 | 清华大学 | 一种制备低分子量肝素的方法 |
CN101495517A (zh) * | 2006-05-25 | 2009-07-29 | 莫曼塔医药品有限公司 | 低分子量肝素及其用途 |
CN102399306A (zh) * | 2010-09-09 | 2012-04-04 | 上海喜恩医药科技发展有限公司 | 一种肝素衍生的多糖混合物的制备方法 |
CN103173506A (zh) * | 2011-10-09 | 2013-06-26 | 清华大学 | 控制生产低分子量肝素的方法 |
CN103540630A (zh) * | 2013-10-22 | 2014-01-29 | 常山生化药业(江苏)有限公司 | 一种低分子量肝素的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1340771A1 (en) * | 2002-02-28 | 2003-09-03 | Nicox S.A | Nitro-derivatives of low molecular weight heparin |
CN101294177B (zh) * | 2008-05-26 | 2012-07-18 | 清华大学 | 一种制备低分子量肝素的方法 |
-
2017
- 2017-05-24 CN CN201710374082.XA patent/CN108117614B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0244236A2 (en) * | 1986-04-30 | 1987-11-04 | Novo Nordisk A/S | Process for the preparation of LMW Heparin |
EP1033375A1 (en) * | 1997-11-20 | 2000-09-06 | Ikuo Yamashina | Low-molecular heparin modification and remedy for skin ulcer |
CN1286266A (zh) * | 2000-09-22 | 2001-03-07 | 复旦大学 | 低抗凝肝素及其衍生物在制备防治肝纤维化药物中的应用 |
CN1712418A (zh) * | 2005-08-04 | 2005-12-28 | 清华大学 | 一种制备低分子量肝素的方法 |
CN101495517A (zh) * | 2006-05-25 | 2009-07-29 | 莫曼塔医药品有限公司 | 低分子量肝素及其用途 |
CN102399306A (zh) * | 2010-09-09 | 2012-04-04 | 上海喜恩医药科技发展有限公司 | 一种肝素衍生的多糖混合物的制备方法 |
CN103173506A (zh) * | 2011-10-09 | 2013-06-26 | 清华大学 | 控制生产低分子量肝素的方法 |
CN103540630A (zh) * | 2013-10-22 | 2014-01-29 | 常山生化药业(江苏)有限公司 | 一种低分子量肝素的制备方法 |
Non-Patent Citations (2)
Title |
---|
Production of heparin oligosaccharides by fusion protein of MBP–heparinase I and the enzyme thermostability;Ying Kuang et al.;《Journal of Molecular Catalysis B: Enzymatic》;20060804;第43卷(第1-4期);第90-95页 * |
低分子量肝素下调转化生长因子转录表达及抗肝纤维化作用;陈公英等;《中国现代应用药学杂志》;20071231;第24卷(第6期);第448页第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN108117614A (zh) | 2018-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0577756A1 (en) | New non-anticoagulant heparin derivatives | |
AU1669592A (en) | New non-anticoagulant heparin derivatives | |
JP2010235956A (ja) | グリコサミノグリカンの製造法 | |
CN108553481B (zh) | 一种具有促进伤口愈合作用的糖类组合物及其应用 | |
KR20070006749A (ko) | 올리고사카라이드, 이의 제조 방법 및 용도, 및 이를함유하는 약학 조성물 | |
JP3929486B2 (ja) | 脱硫酸化多糖の製造法及び脱硫酸化ヘパリン | |
US20190002596A1 (en) | Sulfated heparin oligosaccharide and preparation method and application thereof | |
JP2011526608A (ja) | グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用 | |
Boyce et al. | Production, characteristics and applications of microbial heparinases | |
EP1731131A1 (en) | Hgf production accelerator containing heparin-like oligosaccharide | |
US20060183712A1 (en) | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor | |
US8664196B2 (en) | Shark-like chondroitin sulphate and process for the preparation thereof | |
CA2835691C (en) | Shark-like chondroitin sulphate and process for the preparation thereof | |
CN108117614B (zh) | 低分子量肝素 | |
CA2489862C (en) | Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation | |
CN108117613B (zh) | 低分子量肝素以及肝素用于制备治疗肺纤维化药物的用途 | |
WO2018149320A1 (zh) | 去抗凝肝素衍生物及其用于炎症性肠病的治疗 | |
US20020009782A1 (en) | Heparin and heparan sulfate derived oligosaccharides and a method for their manufacture | |
CN104725532B (zh) | 一种精确定量控制肝素/类肝素中硫酸软骨素及硫酸皮肤素含量的方法 | |
Pecly et al. | Effects of molecular size and chemical structure on renal and hepatic removal of exogenously administered chondroitin sulfate in rats | |
JP2006089632A (ja) | 海洋生物を原料としたヘパリン様物質の調製方法 | |
JP4633233B2 (ja) | クラミジア感染症処置剤 | |
JP2000044601A (ja) | 新規ガラクトサミノグリカン | |
RU2333222C2 (ru) | Эпимеризованные производные полисахарида к5 с высокой степенью сульфатирования | |
JP2007254316A (ja) | Haマトリックス形成阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240102 Address after: Room 3020, 3rd Floor, Building 1, Yard 87, Building Materials City West Road, Changping District, Beijing 102208 Patentee after: Beijing Jushu Biotechnology Co.,Ltd. Address before: Room 612, Building D, Pioneer Park, 2 Shangdi Information Road, Haidian District, Beijing 100085 Patentee before: BEIJING BICHENG BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240625 Address after: Floor 17, Building 2, Liangmahe Building, No. 8 East Third Ring North Road, Chaoyang District, Beijing, 100125 Patentee after: Wuxi Jushu Chuangxing Technology Co.,Ltd. Country or region after: China Address before: Room 3020, 3rd Floor, Building 1, Yard 87, Building Materials City West Road, Changping District, Beijing 102208 Patentee before: Beijing Jushu Biotechnology Co.,Ltd. Country or region before: China |